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Schizophrenia is a chronic psychiatric disorder which substantially impairs patients’
quality of life. Despite the extensive research in this field, the pathophysiology and
etiology of schizophrenia remain unknown. Different neurotransmitter systems and
functional networks have been found to be affected in the brain of patients with
schizophrenia. In this context, postmortem brain studies as well as genetic assays
have suggested alterations in Group II metabotropic glutamate receptors (mGluRs) in
schizophrenia. Despite many years of drug research, several needs in the treatment
of schizophrenia have not been addressed sufficiently. In fact, only 5–10% of patients
with schizophrenia successfully achieve a full recovery after treatment. In recent years
mGluRs have turned up as novel targets for the design of new antipsychotic medications
for schizophrenia. Concretely, Group II mGluRs are of particular interest due to their
regulatory role in neurotransmission modulating glutamatergic activity in brain synapses.
Preclinical studies have demonstrated that orthosteric Group II mGluR agonists exhibit
antipsychotic-like properties in animal models of schizophrenia. However, when these
compounds have been tested in human clinical studies with schizophrenic patients
results have been inconclusive. Nevertheless, it has been recently suggested that this
apparent lack of efficacy in schizophrenic patients may be related to previous exposure
to atypical antipsychotics. Moreover, the role of the functional heterocomplex formed
by 5-HT2A and mGlu2 receptors in the clinical response to Group II mGluR agonists is
currently under study.
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INTRODUCTION
Schizophrenia is a severe, chronic, and disabling mental disorder affecting approximately 0.6% of
the population worldwide (McGrath et al., 2008). Among psychiatric disorders, it is considered
the most disabling one, requiring a disproportionate share of mental health services (Mueser and
McGurk, 2004). Individuals diagnosed with schizophrenia have impaired social and occupational
functioning. Thus, schizophrenia is placed among the world’s top leading causes of years lived with
disability (World Health Organization, 2008; Vos et al., 2015), being also the seventh most costly
medical illness in our society (Freedman, 2003).
The clinical features of schizophrenia are clustered in three categories: positive symptoms,
negative symptoms and cognitive deficits. Positive or psychotic symptoms include delusions (false
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beliefs held with strong conviction in spite of contradictory
evidence), hallucinations (perceptions in the absence of external
stimulus, commonly experienced as hearing voices distinct from
one’s own thoughts), thought disorder (e.g., loose associations),
and abnormal psychomotor activity (e.g., grossly disorganized
behavior, posturing, or catatonia). Negative symptoms comprise
social withdrawal, impairments in initiative and motivation,
a reduced capacity to recognize and express emotional states
and poverty in the amount or content of speech. Cognitive
impairments include disturbances in selective attention,
working memory, executive control, episodic memory, language
comprehension, and social-emotional processing. Symptomatic
onset occurs in late adolescence and early adulthood in males and
somewhat later in females, who tend to be less severely affected
(Abel et al., 2010). The course of schizophrenia is typically
characterized by psychotic exacerbations or relapses alternating
with periods of partial remissions.
The principal pharmacological treatment for schizophrenia is
antipsychotic medication. In general terms, antipsychotic drugs
are effective in reducing the severity of positive symptoms such as
hallucinations and delusions and have made it possible for many
individuals with schizophrenia to live outside hospital settings.
Nevertheless, antipsychotics have minimal impact on both
negative symptoms and cognitive impairments (see Miyamoto
et al., 2012 for review). Thus, the treatment of schizophrenia
with antipsychotics rarely, if ever, produces a cure or entirely
reverses symptoms of the illness. Only 5–10% of persons with
schizophrenia successfully achieve a full recovery with or without
these medications. There is a good response to antipsychotic
medication in 30–40% of patients. However, about 20% are
resistant to standard antipsychotics and an additional 30–40%
show an improvement but are residually symptomatic despite
antipsychotic treatment (Smith et al., 2009).
THE GLUTAMATE HYPOTHESIS OF
SCHIZOPHRENIA
Glutamate is the major excitatory neurotransmitter in the brain.
It interacts with two types of receptors: (i) the ionotropic
receptors, with NMDA, Kainate, and AMPA receptor subtypes
connected to or representing ion channels, and (ii) the
metabotropic glutamate receptors (mGluRs), which activate G
protein-coupled signal transduction and comprising groups I to
III with a total of eight identified subtypes (Nakanishi, 1992).
The observation that the administration of phencyclidine
(PCP) and the dissociative anesthetic ketamine —two NMDA
receptor antagonists— could mimic schizophrenia symptoms
in healthy individuals led to the hypothesis of a functional
impairment of NMDA receptors in this disease (Javitt and Zukin,
1991; Olney and Farber, 1995; Stone et al., 2008). Importantly, it
was described that NMDA receptor antagonists, besides inducing
positive-like symptoms, also found to be induced by other
stimulant drugs such as amphetamine and other dopaminergic
agonists, were also able to evoke cognitive- and negative-like
symptoms (Krystal et al., 2005). Since dopamine release is
under control of NMDA receptors in several brain circuits,
some authors sustain that the glutamatergic dysfunction may
be underlying the dopaminergic deficits found in schizophrenia
(Javitt, 2010).
Additionally, genome-wide association studies have shown
that genes involved in glutamatergic neurotransmission
and synaptic plasticity, e.g., mGluR3 (GRM3), glutamate
ionotropic receptor NMDA type subunit 2A (GRIN2A), serine
racemase (SRR), glutamate ionotropic receptor AMPA type
subunit 1 (GRIA1) or neurogranin (NRGN), are associated
with schizophrenia (Stefansson et al., 2009; Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014).
Moreover, postmortem and neuroimaging studies have found
that several components of glutamatergic signaling system
are affected in schizophrenic patients (Gao et al., 2000; Stone,
2009; Coyle et al., 2012). Thus, drugs targeted to restore the
glutamatergic imbalance could provide better outcomes than
those obtained with current antipsychotics in the treatment of
schizophrenia. In this sense, preclinical and clinical studies have
provided evidence for mGluRs 2, 3, and 5, muscarinic receptors
M1 and M4 or the Glycine transporter GlyT1 among others as
potential targets to retrieve the glutamatergic functioning in
schizophrenia (Field et al., 2011).
GROUP II METABOTROPIC GLUTAMATE
RECEPTORS
Genes encoding eight mGluR subtypes —many of them with
multiple splice variants— have been identified and are classified
into three groups (I–III) according to their sequence homology,
coupling mechanism and pharmacology (Conn and Pin, 1997;
Niswender and Conn, 2010; Figure 1). Group II includes
mGlu2 and mGlu3 receptors, that are coupled predominantly
to Gi/o proteins, which mediate the downstream inhibition of
adenylyl cyclase activity, modulation of voltage-dependent ion
channels (inhibition of calcium and activation of potassium
channels), and the regulation of other downstream signaling
partners via released Gβγ subunits. Recent studies have shown
that Group II mGluRs can also modulate additional signaling
pathways, such as activation of PI3K and MAPK pathways
(Iacovelli et al., 2002; Niswender and Conn, 2010; Nicoletti et al.,
2011).
The mGlu2 and mGlu3 receptors share about 70% of their
amino acid sequence (Pin and Duvoisin, 1995). The gene
encoding the human mGlu2R (GRM2) has been mapped to
chromosome 3p21.1-p21.2 (Marti et al., 2002a). For its part,
mGlu3R gene (GRM3) was mapped to human chromosome
7q21.1-q21.2 (Scherer et al., 1996). While no splicing variants
have been reported for GRM2, alternative splicing has been
described for GRM3 leading to four different variants: full length
mGlu3R, GRM312 (lacking exon 2), GRM314 (lacking exon 4),
and GRM3A213 (lacking exons 2 and 3); being the GRM314 the
most abundant one (Sartorius et al., 2006). Despite this variant
lacks the transmembrane domain—which is encoded by exon
4— it has been shown that it can be translated in cells, thus
suggesting its potential function as a unique glutamate receptor
(Niswender and Conn, 2010).
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FIGURE 1 | Classification and sequence homology dendrogram of mGluRs. The known splice variants and main signaling pathways are indicated. –AC,
inhibition of adenylyl cyclase activity; +PLC, activation of phospholipase C.
Group II mGluRs are widely expressed throughout the
central nervous system. The expression levels are moderate to
high in different brain regions such as the prefrontal cortex
(PFC), the dorsal and ventral striatum, the thalamus, the
hippocampus, and the amygdala (Petralia et al., 1996; Wright
et al., 2001; Gu et al., 2008); regions that have been shown to
be involved in cognition and emotional states. The mGlu3Rs
expression across these regions is more disperse than that
of mGlu2Rs (Ohishi et al., 1993; Gu et al., 2008). In the
PFC mGlu2Rs present a high but restricted expression with a
bilaminar distribution in layer I and layer Va while mGlu3Rs
distribution is more homogenous throughout the cortex with
a slight higher expression in layers I–III than in layers IV–VI
(Marek, 2010). At the neuronal level, mGlu2Rs are localized
at the perisynapse (Cartmell and Schoepp, 2000) mainly acting
as autoreceptors where they function as a feedback negative
mechanism to suppress the excessive glutamate release keeping
the homeostasis of the synapse (Cartmell and Schoepp, 2000;
Schoepp, 2001). However, both presynaptic and postsynaptic
cortical immunoreactivity of mGlu2Rs has been described. For
its part mGlu3Rs immunoreactivity has been shown mainly
presynaptic (Neki et al., 1996; Ohishi et al., 1998; Tamaru et al.,
2001) and whereas mGlu2Rs expression is restricted to neurons,
mGlu3Rs are also found on glial cells (Ohishi et al., 1993; Tamaru
et al., 2001) where they may interact with glutamate transporters
(Aronica et al., 2003).
Besides modulation of glutamate physiology, Group II
mGluRs, also control the neurotransmitter release of other
systems acting as heteroreceptors in GABAergic, dopaminergic,
noradrenergic, or serotonergic synapses (Cartmell and Schoepp,
2000).
A limited number of molecules possess agonist activity across
all mGluRs. The endogenous agonist L-glutamate, L-CCG-I
[(2S,10 S,20 S)-2-(carboxycyclopropyl)glycine] and ABHxD-I
(2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I) are the
most potent (Acher, 2011). More recently, systemically active
and highly selective agonists of Group II mGluRs have been
developed, providing valuable insights into the in vitro and
in vivo functions of these receptors (Niswender and Conn, 2010).
LY354740 ((1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2, 6-di-
carboxylic acid) was the first Group II mGluR selective agonist
reported to exhibit a nanomolar affinity (Monn et al., 1997).
It has been followed by more recent compounds, including
LY379268 ((1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-
2,6-dicarboxylic acid), now a commonly used tool for studies
of Group II mGluR function (Schoepp et al., 1999). These
compounds are highly selective for Group II mGluRs relative to
other mGluR subtypes but do not differentiate between mGlu2R
and mGlu3R. Other Group II selective agonists have been
described with submicromolar affinity, including (2R,4R)-APDC
((2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate) and DCG-IV
((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine). Additiona-
lly, an analog of LY354740 with a methyl substituent at
the C4α-position was reported to have mGlu2R agonist
and mGlu3R antagonist activity (Dominguez et al., 2005).
Thus far, no orthosteric antagonists have been discovered
that are entirely specific for Group II mGluRs. However,
LY341495 ((2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]
-3-(xanth-9-yl) propanoic acid) provides relatively high
selectivity with nanomolar potency as a Group II
mGluR antagonist with submicromolar to micromolar
potencies at all other mGluR subtypes (Schoepp et al.,
1999).
To date, besides orthosteric ligands, multiple selective
positive allosteric modulators (PAMs) of mGlu2R have been
identified. The majority are structurally related to either
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LY487379 (2,2,2-trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-
(3-pyridinylmethyl)ethanesulfonamide hydrochloride) or BINA
(biphenyl-indanone A), two prototypical mGlu2R PAMs (Conn
et al., 2009; Niswender and Conn, 2010). Many of these
compounds are highly selective for mGlu2R and do not potentiate
responses to activation of mGlu3R or any other mGluR subtype
(Cid et al., 2015). In addition, group II mGluR negative allosteric
modulators (NAMs) have also been developed, but in this case
acting at both mGlu2R and mGlu3R (Hemstapat et al., 2007;
Woltering et al., 2008a,b).
ALTERATIONS OF GROUP II mGluRs IN
SCHIZOPHRENIA
Postmortem Brain Studies
Different approaches have been used to determine the possible
alterations of both, mRNA and protein expression, of Group
II mGluRs in the postmortem brain of schizophrenic subjects.
The majority of the findings suggest that the level of expression
of GRM3 mRNA is unaffected in schizophrenia (Ohnuma
et al., 1998; Richardson-Burns et al., 2000; Egan et al., 2004;
Bullock et al., 2008; Ghose et al., 2008; Gonzalez-Maeso et al.,
2008). Fewer studies have investigated GRM2 mRNA expression
in postmortem human brain of schizophrenic subjects. Semi-
quantitative approaches such as in situ hybridization have
reported unaffected levels of GRM2 mRNA in thalamus
(Richardson-Burns et al., 2000), and higher GRM2 mRNA
expression in the PFC white matter (Ghose et al., 2008).
However, quantitative real-time PCR assays showed lower level
of expression of GRM2 mRNA in the PFC (Gonzalez-Maeso
et al., 2008) and cerebellum (Bullock et al., 2008) of schizophrenic
subjects.
Studies using immunolabeling techniques have reported
different outcomes in regard to Group II mGluRs protein
expression levels in schizophrenia. Differentiation of mGlu3R
from mGlu2R has been problematic because of the lack of
selective ligands and antibodies. An early study, using non-
specific antibodies that detect both mGlu2 and mGlu3 receptor
proteins, found no change in mGlu2/3R expression in the
PFC (BA46) of schizophrenic subjects compared to controls
(Crook et al., 2002). A second study, using also non-specific
antibodies, found a significant increase in mGlu2/3R expression
in the BA46 of schizophrenic subjects compared to controls,
but not in other cortical regions including BA9 and BA11
(Gupta et al., 2005). The availability of specific antibodies
allowed the evaluation of the protein expression of each subtype
of Group II mGluRs. Corti et al. (2007) found a significant
decrease in the dimeric form of mGlu3Rs in the PFC (BA10)
of schizophrenic subjects compared to controls, with unaffected
levels of the monomeric forms. Similarly, another study reported
a decrease in mGlu3R protein in the PFC (BA46) of schizophrenic
subjects, but not in other areas such as temporal or motor
cortices (Ghose et al., 2009). This study reported unchanged
mGlu2R protein expression in schizophrenia (Ghose et al.,
2009), however, the antibody used to assess the mGlu2R
immunoreactivity was not previously validated and was actually
measuring the subtype 2 of the AMPA ionotropic glutamate
receptor1.
Four independent studies have investigated the radioligand
binding density of mGlu2/3Rs in the postmortem brain of
schizophrenic subjects. Gonzalez-Maeso et al. (2008), reported a
decrease in the binding density of mGlu2/3Rs in the PFC (BA9)
of schizophrenic subjects respect to matched controls using the
mGlu2/3R antagonist [3H]LY341495. Other studies, however,
reported no differences in mGlu2/3R binding density in the PFC
(BA46) between schizophrenic subjects and controls when using
either the mGlu2/3R agonist [3H]LY354740 (Frank et al., 2011)
or the antagonist [3H]LY341495 (McOmish et al., 2016). Two
studies have evaluated the mGlu2/3Rs density in other areas
besides PFC, founding no differences between schizophrenia and
control groups neither in the anterior cingulated cortex (BA24;
Matosin et al., 2014; McOmish et al., 2016) nor in the visual cortex
(BA17; McOmish et al., 2016).
Taking into account the different findings from postmortem
studies the status of Group II mGluRs in schizophrenia remains
unclear. Thus, further investigation of the level of expression
and function of mGlu2/3Rs in postmortem human brain of
schizophrenic subjects and controls is needed.
Genetic Studies
While other factors besides genetics are definitely involved,
investigation of the genetic alterations responsible for
schizophrenia represents a useful approach to better understand
the cause of the disease (Harrison and Weinberger, 2005). As
mentioned above, mGlu2R gen (GRM2) has been mapped to
chromosome 3p21.1–p21.2 (Marti et al., 2002a), and linkage
studies of schizophrenia show no positive results regarding
this region (Moreno et al., 2009). Moreover, in a population-
based genetic study for candidate polymorphisms in alleles
of the mGlu2R gene, no association was found between such
polymorphisms and schizophrenia (Joo et al., 2001).
Genetic association analyses have consistently suggested
an association between SNPs in the mGlu3R gene (GRM3)
and schizophrenia (Fujii et al., 2003; Egan et al., 2004;
Chen et al., 2005; Sartorius et al., 2008; Cherlyn et al.,
2010) including a recent multi-stage schizophrenia genome-
wide association study (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014). However, this
association was not replicated in other population-based genetic
studies (Marti et al., 2002b; Tochigi et al., 2006). GRM3
polymorphisms associated with schizophrenia are often located
in a non-coding region. Therefore, the mechanism underlying the
association between GRM3 and schizophrenia is not clear. GRM3
polymorphisms have been associated with negative symptom
improvement during olanzapine treatment (Bishop et al., 2005).
Egan et al. (2004) proposed a specific pathway by which
GRM3 genotype could alter the glutamatergic transmission
leading to an increase in the risk for schizophrenia. These
authors found an association between an intronic variation
in GRM3 and a reduced performance on cognitive tests of
1http://www.abcam.com/Ionotropic-Glutamate-receptor-2-antibody-
ab52176.html
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prefrontal and hippocampal function, which are schizophrenia
related phenotypes. Moreover, in postmortem human PFC,
GRM3 variant carriers showed lower mRNA levels of the glial
glutamate transporter EAAT2. Therefore, authors suggest that
the pathophysiological mechanism underlying schizophrenia
may involve altered mGlu3 transcription/expression and altered
glutamate neurotransmission related to a reduced expression of
the glial glutamate transporter EAAT2 (Egan et al., 2004).
GROUP II mGluRs AS TARGETS FOR
NOVEL ANTIPSYCHOTIC DRUGS
Metabotropic glutamate receptors have received significant
interest as potential drug targets. Such interest is due to the
belief that metabotropic receptor targeting provides a way
for modulating glutamate tone and phasic release in a more
subtle manner than that which can be achieved through
glutamate ionotropic receptors. Specifically, emerging preclinical
and clinical data suggest that activation of Group II mGluRs is a
mechanistically novel and promising approach for the treatment
of schizophrenia (Marek, 2004; Harrison, 2008; Krivoy et al.,
2008; Sodhi et al., 2008; Conn et al., 2009; Chaki, 2010; Fell et al.,
2012; Vinson and Conn, 2012; Wieron´ska et al., 2016).
Preclinical Evidences of Antipsychotic
Activity
Extensive preclinical data proved that orthosteric Group II
mGluR agonists, including LY354740, LY379268, and LY404039
exhibit antipsychotic-like properties in animal models of
schizophrenia. The dissociative drugs PCP and ketamine have
been shown to increase the activity of glutamatergic synapses in
the PFC (Adams and Moghaddam, 1998; Lorrain et al., 2003)
and different studies have confirmed that Group II mGluR
agonists are able to reverse this effect (Moghaddam and Adams,
1998; Marek et al., 2000; Lorrain et al., 2003). It has been
also shown that the systemic administration of the mGlu2/3R
agonists LY379268 and LY404039 is able to increase dopamine
extracellular levels in rodent’s frontal cortex (Cartmell et al., 2001;
Rorick-Kehn et al., 2007b). Increases in cortical dopamine levels
have been linked to the improvement of negative symptoms in
schizophrenia. Additionally, atypical antipsychotic drugs such
as clozapine and risperidone also produce a cortical increase of
this neurotransmitter (Cartmell et al., 2001). Besides dopamine,
cortical serotonin is also enhanced by the systemic administration
of mGlu2/3R agonists as well as by the atypical antipsychotic
risperidone (Cartmell et al., 2001; Rorick-Kehn et al., 2007b).
These neurochemical similarities between mGlu2/3R agonists
and already known antipsychotic drugs provide support for the
potential antipsychotic properties of the firsts.
In addition to this neurochemical evidence, Group II
mGluR agonists have also shown the ability to reverse the
behavioral effects induced by psychotomimetic drugs in several
animal models predicting their potential as antipsychotic agents
(Wieron´ska et al., 2016). In this sense, locomotor response
to psychostimulants in rodents represents an animal correlate
of schizophrenia positive symptoms (Arguello and Gogos,
2006). Regarding this aspect, the mGlu2/3R agonist LY354740
administered at a dose that did not affect spontaneous locomotor
activity itself has proved to attenuate PCP-induced locomotor
hyperactivity and stereotypies (Moghaddam and Adams, 1998).
Similar results have been reported with other mGlu2/3R agonists,
like LY404039 (Rorick-Kehn et al., 2007a,b), LY379268 (Cartmell
et al., 2000), MGS0008 and MGS0028 (Nakazato et al., 2000).
Moreover, the hyperactivity induced by amphetamine has also
been shown to be inhibited by both LY379268 and LY404039
(Galici et al., 2005; Rorick-Kehn et al., 2007a,b). Furthermore,
the agonists MGS0008, MGS0028, and LY404039 have been
reported to inhibit conditioned avoidance responses (Takamori
et al., 2003; Rorick-Kehn et al., 2007b) and LY354740 has also
shown ability to prevent the PCP-induced deficits on a working
memory task (Moghaddam and Adams, 1998), a paradigm
that correlates with the cognitive dimension of schizophrenia
symptoms (Arguello and Gogos, 2006). Interestingly, Group II
mGluR agonists have also been shown to reverse the effects
induced by 5-HT2AR hallucinogenic agonists. Thus, mGlu2/3R
orthosteric agonists, such as LY379268 and LY354740, reduce
the cellular (Zhai et al., 2003; Gonzalez-Maeso et al., 2008),
electrophysiological (Marek et al., 2000) and behavioral (Gewirtz
and Marek, 2000; Gonzalez-Maeso et al., 2008) effects induced
by the hallucinogen 2,5-Dimethoxy-4-iodoamphetamine (DOI).
Similar findings have been reported for the selective mGlu2R
positive allosteric modulator (PAM) BINA (Benneyworth et al.,
2007). In fact, in recent years, more attention has been paid to
mGluRs PAMs, especially to those selective for mGlu2R subtype
(Ellaithy et al., 2015). In this sense, several preclinical studies
have shown efficacy for selective mGlu2R PAMs, i.e., CBiPES,
JNJ-40411813, JNJ-42153605, and TASP0433864, in reversing
psychotic-like symptoms (Johnson et al., 2005; Hiyoshi et al.,
2014; Hikichi et al., 2015; Lavreysen et al., 2015). All of the
above-mentioned findings support the potential use of mGlu2/3R
agonists for the treatment of schizophrenia symptoms.
In regard to Group II mGluR agonists’ selectivity, Seeman
et al. (2008) have suggested that the antipsychotic effects of these
compounds may be due to their affinity for D2 receptors (Seeman
et al., 2008). However, other laboratories have convincingly
demonstrated that this direct effect of Group II mGluR agonists
over dopamine receptors is not replicable (Fell et al., 2009; Zysk
et al., 2011). In terms of subtype selectivity, it has been suggested
that the antipsychotic effects exerted by Group II mGluR agonists
are mediated by mGlu2R rather than by mGlu3R (Woolley
et al., 2008; Fell et al., 2012; Vinson and Conn, 2012). This
hypothesis is based on the results obtained in studies performed
with mGlu2R-KO and mGlu3R-KO mice. Thus, antipsychotic
actions of Group II agonists LY404039 and LY314582 (racemic
mixture of LY354740) were absent in mGlu2R-KO mice but
present in mGlu3R-KO mice, strongly implicating mGlu2R as
the predominant player in this effect (Spooren et al., 2000; Fell
et al., 2008). Similar results were observed for the Group II
agonist LY379268 that reversed PCP- and amphetamine-evoked
hyperactivity in wild type and mGlu3R-KO mice but not in
mGlu2R-KO mice (Woolley et al., 2008). This finding is further
supported by the results observed with selective mGlu2R PAMs
mentioned above, which have shown efficacy in animal behavioral
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paradigms used to assess the antipsychotic activity regarding both
positive-like symptoms and cognitive impairments (Johnson
et al., 2003; Galici et al., 2005, 2006, Govek et al., 2005; Johnson
et al., 2005; Pinkerton et al., 2005; Benneyworth et al., 2007;
Duplantier et al., 2009; Hiyoshi et al., 2014; Hikichi et al., 2015;
Lavreysen et al., 2015). The action of PAMs depends on the
presence of a threshold level of agonist, since they do not activate
the receptor directly. Hence, it has been postulated that PAMs
may provide a safer and better tolerated therapeutic profile than
orthosteric compounds, with a more regulated action and a
lower potential receptor desensitization (Johnson et al., 2005;
Urwyler, 2011). On the other hand, mGlu3Rs have been recently
postulated as potential targets to treat the cognitive dysfunction
in schizophrenia. Walker et al. (2015) showed that mGlu3Rs
can influence synaptic plasticity within mice PFC and that the
specific blockade of this receptor impairs learning in a mPFC-
dependent fear extinction task. Thus, these authors propose
selective PAMs of mGlu3Rs as a novel therapeutic strategy for
enhancing prefrontal function in schizophrenic patients (Walker
et al., 2015).
Clinical Evidences of Antipsychotic
Activity
The selective Group II mGluR agonists have been well-
characterized and optimized and have entered into clinical trials
for treatment of schizophrenia. The oral prodrug of LY404039,
(1R,4S,5S,6S)-2-thiabicyclo[3.1.0]- hexane-4,6-dicarboxylic acid,
4-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino-, 2,2-dioxide
monohydrate (LY2140023) developed by Eli Lilly and Co, showed
significant antipsychotic efficacy for both positive and negative
symptoms with no major side effects in a trial involving
patients suffering from schizophrenia and also showed a better
metabolic profile than the comparator olanzapine (Patil et al.,
2007). Unfortunately, in the follow-up study, neither LY2140023
nor the comparator olanzapine were more efficacious than
placebo as measured by the Positive and Negative Syndrome
Scale (PANSS) total score due to higher-than expected placebo
response (Kinon et al., 2011), thus, the results of this study were
considered to be inconclusive (Kinon et al., 2011). In a more
recent multicenter, randomized, double-blind, phase II study,
LY2140023 monohydrate was again tested against placebo and
the active control risperidone in schizophrenic patients with an
acute exacerbation of symptoms. The primary outcome assessed
change from baseline in the PANSS total score in an overall
schizophrenia population and a predefined subpopulation which
excluded non-Hispanic white patients with the A/A genotype
at the serotonin 2A receptor (5-HT2AR) single nucleotide
polymorphism rs7330461 (Downing et al., 2014). Neither
LY2140023 dose showed significant improvement compared to
placebo in either population. Conversely, risperidone showed
a better efficacy than placebo in both populations (Downing
et al., 2014). Finally, another study found no benefit of adjunctive
treatment with LY2140023 versus placebo for negative symptoms
in patients with schizophrenia receiving treatment with second-
generation antipsychotics (Stauffer et al., 2013). The mGlu2R
PAM JNJ-40411813/ADX71149 from Janssen Pharmaceuticals,
Inc. and Addex Therapeutics has also been evaluated in
clinical trials for schizophrenia treatment. Data reported in
2012 showed that JNJ-40411813/ADX71149 met the primary
objectives of safety and tolerability and demonstrated an effect
in patients with residual negative symptoms (Hopkins, 2013).
The latest data in two phase-1 studies showed efficacy of the
drug reducing the continuity of attention score, improving the
quality of episodic memory and reducing the ketamine-induced
negative symptoms in healthy volunteers (Salih et al., 2015).
Another mGlu2R PAM that has advanced into clinical trials
is the AZD8529 from AstraZeneca. Despite this compound
failed to be effective in a phase 2 study when administered
as monotherapy at a single dose in schizophrenic patients, it
remains to be determined whether different treatment regimens
or adjunct treatment would provide benefit (Litman et al.,
2014).
THE ROLE OF THE 5-HT2AR/mGlu2R
HETEROCOMPLEX
5-HT2AR and mGlu2R have been both implicated in the
pathophysiology of schizophrenia and also have been considered
as targets for antipsychotic drug development. Previous
electrophysiological (Marek et al., 2000), cellular (Benneyworth
et al., 2007), neurochemical (Martin-Ruiz et al., 2001), and
behavioral (Gewirtz and Marek, 2000) data have suggested an
interaction between 5-HT2A and mGlu2 receptors. At present,
it has been convincingly proved the existence of a specific
functional heteromeric complex formed by 5-HT2A and mGlu2
receptors through which serotonin and glutamate ligands
modulate the pattern of G protein-coupling in living cells
(Gonzalez-Maeso et al., 2008; Moreno et al., 2012; Baki et al.,
2016).
This serotonin-glutamate heterocomplex has been
involved in the mechanism of action of both hallucinogenic
(Gonzalez-Maeso et al., 2003, 2007; Moreno et al., 2011a) and
antipsychotic drugs (Fribourg et al., 2011). Thus, it has been
reported that mGlu2R is necessary for at least some of the
cellular and behavioral responses induced by hallucinogenic
5-HT2AR agonists such as lysergic acid diethylamide (LSD).
It has been shown in [35S]GTPγS binding assays followed by
immunoprecipitation with anti-Gq/11 or anti-Gi1,2,3 antibodies
that the hallucinogenic 5-HT2AR agonist DOI activates both
Gq/11 and Gi proteins only when the 5-HT2AR is expressed as
a receptor heterocomplex with the mGlu2R (Gonzalez-Maeso
et al., 2008). Moreover, the head-twitch response was not
produced by the hallucinogens DOI and LSD in mGlu2R-KO
mice (Moreno et al., 2011a). Furthermore, it has been recently
proved that the disruption of heteromeric expression with
mGlu2R attenuates the psychosis-like effects induced in mice by
hallucinogenic 5-HT2AR agonists (Moreno et al., 2012; Figure 2).
These authors, not only validate the 5-HT2A/mGlu2 receptor
heterocomplex as necessary for the behavioral effects induced by
LSD-like drugs in rodents, but also provide the first evidence for
the specific residues responsible for a G protein-coupled receptor
(GPCR) heteromeric complex formation (Moreno et al., 2012).
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FIGURE 2 | G protein-dependent signaling and behavioral responses that require the 5-HT2AR/mGlu2R heterocomplex. LSD acting at the
5-HT2AR/mGlu2R heterocomplex activates both Gq/11- and Gi/o-dependent signaling. In contrast, when 5-HT2AR and mGlu2R are prevented from forming a
receptor heterocomplex, activation of 5-HT2AR by LSD elicits characteristic signaling of Gq/11-protein subtypes. Head-twitch behavior is reliably and robustly elicited
by hallucinogenic 5-HT2AR agonists, and is absent in mGlu2R-KO mice. Adapted from Gonzalez-Maeso (2011).
Atypical antipsychotic drugs, such as clozapine and
risperidone, have a high affinity for the serotonin 5-HT2AR,
which preferred signaling pathway is via Gq/11 proteins.
Closely related non-antipsychotic drugs, such as ritanserin
and methysergide, also block 5-HT2AR function, but they lack
comparable neuropsychological effects. In this regard, it has
been reported that these ligands inputs are actually integrated by
the 5-HT2AR/mGlu2R heterocomplex that modulates signaling
outputs and behavioral changes (Fribourg et al., 2011). Thus,
serotonergic and glutamatergic drugs would bind to the 5-
HT2AR/mGlu2R heterocomplex, which then balances Gi/o-
and Gq/11-dependent signaling. The authors also state that
5-HT2AR/mGlu2R -mediated changes in Gi/o and Gq/11 activity
could predict the psychoactive behavioral effects of different
pharmacological compounds.
Importantly, it has been demonstrated a dysregulation in the
binding density of the receptors comprising this heterocomplex
in postmortem PFC of schizophrenic subjects (Gonzalez-Maeso
et al., 2008). Thus, increased 5-HT2AR and decreased mGlu2/3R
binding was found in schizophrenic subjects compared to
matched controls (Gonzalez-Maeso et al., 2008). Interestingly,
5-HT2AR density was comparable to control values in those
subjects that were under antipsychotic treatment at time
of death, whereas mGlu2/3R density remains decreased.
Furthermore, the ligand binding interaction between the
components of the 5-HT2A/mGlu2 receptor heterocomplex was
found up-regulated in the postmortem PFC of schizophrenic
subjects as compared with controls (Moreno et al., 2012).
Additionally, at the level of signaling, a recent study by same
authors showed that mGlu2R-dependent activation of Gq/11,
but not Gi/o proteins, is reduced in the postmortem PFC
from schizophrenic patients (Moreno et al., 2016). Moreover,
recent studies have reported altered densities and behavioral
functions of 5-HT2A and mGlu2 receptors in different animal
models that resemble some aspects of schizophrenia. Thus,
in frontal cortex of mice born to influenza virus-infected
mothers, stressed mothers or lipopolysaccharide (LPS)-treated
mothers the 5-HT2AR is upregulated (Moreno et al., 2011b;
Holloway et al., 2013; Wischhof et al., 2015) and the mGlu2R
receptor is downregulated (Moreno et al., 2011b; Holloway
et al., 2013). Furthermore, these changes are translated into
behavioral alterations, since increased head-twitch response
to the hallucinogenic 5-HT2AR agonist DOI and decreased
mGlu2-dependent antipsychotic-like effect of the mGlu2/3
agonist LY379268 were observed in these three studies
(Moreno et al., 2011b; Holloway et al., 2013; Wischhof et al.,
2015).
A pharmacogenetic analysis of the efficacy of LY2140023
monohydrate in the treatment of schizophrenia has
demonstrated a genetic association between several single
nucleotide polymorphisms located in the gene encoding the
5-HT2AR and the response to LY2140023 treatment (Liu et al.,
2012). Thus, a 30-point PANSS total reduction was seen in
schizophrenic patients in the most responsive genotype group
that presented the single nucleotide polymorphism rs7330461
for the 5-HT2AR gene (Liu et al., 2012). Additionally, a recent
study has confirmed that the T/T genotype at rs7330461 is
consistently associated with an increased treatment response to
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pomaglumetad methionil (LY2140023) compared to the A/A
genotype (Nisenbaum et al., 2016).
All these facts point to a putative role of the 5-HT2AR/mGlu2R
heterocomplex in the antipsychotic-like properties of the Group
II mGluR agonists that could also explain the controversial
results reported in clinical trials. In this way, it has been
demonstrated that chronic atypical antipsychotics downregulate
the transcription of mGlu2R through epigenetic modifications
(Kurita et al., 2012). This change occurs in concert with
a 5-HT2AR-dependent up-regulation and increased binding
of histone deacetylase 2 to the mGlu2 promoter (Kurita
et al., 2012). This decrease in the mGlu2R expression could
induce a lower response to Group II mGluR agonists
as LY2140023 in patients previously treated with atypical
antipsychotics. Accordingly, a recent study has reanalyzed
previous clinical data on LY2140023 treatment defining two
patients subpopulations based upon medication exposure
during the 2 years before study entry (Kinon et al., 2015).
This analysis has demonstrated that patients previously
treated with antipsychotics with prominent dopamine 2
receptor antagonist activity who were subsequently treated
with LY2140023 monohydrate showed a significantly greater
improvement on the PANSS total score from baseline than
placebo treated patients. Conversely, patients previously treated
with antipsychotics with prominent 5-HT2AR antagonist
activity demonstrated no greater response than placebo
(Kinon et al., 2015). Thus, as LY2140023 monohydrate
treatment is targeted to mGlu2R receptor activation it will
induce lower efficacy if the mGlu2R receptor levels are




Several studies have showed that Group II mGluR agonists
exhibit antipsychotic-like properties in preclinical assays.
However, when these compounds have been used in human
clinical trials the results have been controversial. Recent data
suggest that this apparent lack of efficacy in schizophrenic
patients may be related to previous exposure to atypical
antipsychotics. Moreover, pharmacogenetic assays have
demonstrated the influence of genetic variants on response to
Group II mGluR agonists in patients with schizophrenia. The fact
that Group II mGluRs represent a new target for the treatment
of schizophrenia supports the need for additional investigation
to establish the real efficacy of these new compounds. Moreover,
it is mandatory to clarify if specific subgroups of patients could
obtain a greater benefit from using these new drugs.
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